# Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

Study · id `cardio:ct-nct03030235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03030235](<https://clinicaltrials.gov/study/NCT03030235>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03030235

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

## Technical summary

Registry record NCT03030235. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-01 (actual); primary completion 2021-08-13 (actual). Results posted on 2022-10-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 324 participants (enrolled count; ClinicalTrials.gov record NCT03030235, source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)
- Started: 2017-03-01 (actual) (ClinicalTrials.gov record NCT03030235, source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)
- Primary completion: 2021-08-13 (actual) (ClinicalTrials.gov record NCT03030235, source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)
- Completion: 2021-08-13 (actual) (ClinicalTrials.gov record NCT03030235, source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)
- Results first posted: 2022-10-19 (ClinicalTrials.gov record NCT03030235, source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03030235, source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03030235-2022-10-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
- Acronym: PRESERVED-HF
- Condition: Chronic Heart Failure With Preserved Systolic Function
- Intervention (Drug): Dapagliflozin 10Mg Oral Tablet
- Intervention (Drug): Dapagliflozin matching placebo
- Lead sponsor: Saint Luke's Health System
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Saint Luke's Health System (`cardio:org-saint-luke-s-health-system`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial (`cardio:pubmed-34711976`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF (`cardio:pubmed-37869881`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial (`cardio:pubmed-38639697`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cfb070eb77b69668a79554ae1e399d476543f5256a9ef5d24420d2dc8e8b0ddb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
